Early diagnosis and treatment of cervical cancer vaccine system

Status

Active, not recruiting

Phases

Phase 3

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OIC-16008915

Enrollment

Unknown

Registered

2016-07-26

Start date

2016-09-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer

Interventions

Trial group:Autologus Dendritic Cell

Eligibility

Sex/Gender

Female

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. recurrent cervical cancer; 2. HPV 16/18 infection; 3. Previously received cisplatin or 5-FU based chemotherapy or refused to receive chemotherapy; 4. HLA-A2 haplotype; 5. Older than 20 years old; 6. ECOG I or II; 7. Life expectancy longer than 3 months; 8. Adequate bone marrow reserve; 9. Negative finding in pregnancy test; 10. Informed consent obtained.

Exclusion criteria

Exclusion criteria: 1. CNS metastasis; 2. Acute or chronic infection; 3. Pregnant or lactating women; 4. Asthma; 5. Cardiac diseases such as heart failure, unstable angina, arrhythmia, myocardial infarction; 6. Autoimmune disease; 7. Previously other cancers (except basal cell cancer); 8. Without chemotherapy, biotherapy for more than 6 weeks.

Design outcomes

Primary

Measure	Time frame
HPV clearance;	—

Countries

China

Contacts

Public ContactLuo Jin

Jiangsu Antae Biological Technology Co., Ltd

744819556@qq.com+86 15896003688

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026